Cabaletta Bio (NASDAQ:CABA – Get Free Report) had its target price dropped by stock analysts at Citigroup to $8.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup‘s price objective would indicate a potential upside of 451.72% from the company’s previous close.
A number of other equities research analysts have also issued reports on CABA. William Blair raised Cabaletta Bio to a “strong-buy” rating in a research report on Wednesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Thursday, October 15th. TD Cowen raised Cabaletta Bio to a “strong-buy” rating in a research report on Monday, August 24th. Wells Fargo & Company reduced their price target on Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, August 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Cabaletta Bio in a research note on Tuesday, September 1st. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $14.33.
Read Our Latest Research Report on CABA
Cabaletta Bio Stock Performance
Cabaletta Bio (NASDAQ:CABA – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. Equities research analysts expect that Cabaletta Bio will post -1.27 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Private Advisor Group LLC grew its stake in Cabaletta Bio by 22.4% in the first quarter. Private Advisor Group LLC now owns 18,025 shares of the company’s stock valued at $48,000 after purchasing an additional 3,300 shares in the last quarter. Voya Investment Management LLC raised its stake in shares of Cabaletta Bio by 47.6% during the 3rd quarter. Voya Investment Management LLC now owns 31,557 shares of the company’s stock worth $61,000 after purchasing an additional 10,180 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Cabaletta Bio during the 2nd quarter worth approximately $34,000. HighTower Advisors LLC acquired a new stake in shares of Cabaletta Bio in the 2nd quarter valued at approximately $34,000. Finally, WINTON GROUP Ltd boosted its holdings in shares of Cabaletta Bio by 76.5% in the 2nd quarter. WINTON GROUP Ltd now owns 27,000 shares of the company’s stock valued at $84,000 after buying an additional 11,700 shares during the last quarter.
Cabaletta Bio News Roundup
Here are the key news stories impacting Cabaletta Bio this week:
- Positive Sentiment: Cabaletta presented new Phase 1/2 data for rese-cel at ACR Convergence 2026. A related report characterized the autoimmune-disease results as positive, which may reinforce investor interest in the company’s clinical program. Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data At ACR Convergence 2026
- Positive Sentiment: HC Wainwright raised its earnings estimates across several future periods, projecting smaller per-share losses, including for fiscal 2027–2029. The firm maintained its Buy rating and $16 price target, an optimistic view that could support sentiment. Cabaletta Bio analyst coverage
- Neutral Sentiment: A short-interest report listed zero shares sold short as of November 10, making its accompanying claim of a significant increase internally inconsistent; it offers no reliable indication of short-selling pressure.
- Negative Sentiment: Citigroup lowered its price target to $8, although it retained a Buy rating. The reduced target may temper enthusiasm despite remaining above the price cited in the report. Citigroup stock recommendations
About Cabaletta Bio
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression. Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.
Further Reading
- Five stocks we like better than Cabaletta Bio
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.
